ArticlePharmaceutics2026

Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics.

David Bibi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.